drugset

drugset / Trial / NCT03975907

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

NCT03975907 ↗

Phase 1/2 Unknown 121 enrolled CARsgen Therapeutics Co., Ltd. Beijing Chao Yang Hospital · collab Beijing Hospital · collab First Affiliated Hospital of Wenzhou Medical University · collab First Affiliated Hospital of Zhejiang University · collab First Affiliated Hospital, Sun Yat-Sen University · collab Peking University People's Hospital · collab Qilu Hospital of Shandong University · collab Shanghai Tongji Hospital, Tongji University School of Medicine · collab Sun Yat-sen University · collab The First Affiliated Hospital of Soochow University · collab Tianjin Medical University General Hospital · collab Xiangya Hospital of Central South University · collab Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT053 CAR-BCMA T in patients with relapsed and/or refractory multiple myeloma.

Timeline

Start: 2019-06-10
Primary completion: 2024-12-31
Completion: 2025-12-31

Publications

Fu C, Chen W, Cai Z, Yan L, Wang H, Shang J, Wu Y, Yan S, Gao W, Shi X, Han X, Tang F, Zheng G, Wen Y, Meng X, Yuan D, Wang H, Li Z. Long-term follow-up of zevor-cel in patients with relapsed/refractory multiple myeloma. Blood Adv. 2026 Jan 27;10(2):468-478. doi: 10.1182/bloodadvances.2025017365.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	zevorcabtagene autoleucel	Cell therapy	1e+08 cells	—
Subject	zevorcabtagene autoleucel	Cell therapy	1.5e+08 cells	—

Indications